ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04385849
- Locations
- 🇺🇸
St. Francis, Lynwood, California, United States
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT04052061
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04050709
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03853317
- Locations
- 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03647423
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.080: NANT Pancreatic Cancer Vaccine
- Conditions
- Interventions
- Drug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionBiological: bevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: OxaliplatinBiological: AvelumabProcedure: SBRT
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03586869
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Interventions
- Drug: Nab-paclitaxelDrug: GemcitabineDrug: Aldoxorubicin HClBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: BevacizumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Oxaliplatin
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
- Conditions
- Interventions
- Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabDrug: CapecitabineDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: nab-PaclitaxelDrug: SorafenibProcedure: SBRTBiological: Aldoxorubicin hydrochlorideBiological: ETBX-051Biological: ETBX-061Biological: GI-6207Biological: GI-6301Drug: CetuximabBiological: N-803
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563170
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States